PLA2G4F
Gene Information
- Official Symbol: PLA2G4F
- Official Name: phospholipase A2 group IVF
- Aliases and Previous Symbols: N/A
- Entrez ID: 255189
- UniProt: Q68DD2
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: N/A
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Calcium-dependent phospholipase A2 that selectively hydrolyzes glycerophospholipids in the sn-2 position. Has higher enzyme activity for phosphatidylethanolamine than phosphatidylcholine (By similarity). {ECO:0000250}.
Pfam Domains GO Terms
Pfam Domains
| PLA2 B |
| C2 |
GO Terms
| calcium-dependent phospholipase A2 activity |
| phosphatidylinositol acyl-chain remodeling |
| phosphatidylglycerol acyl-chain remodeling |
| prostanoid biosynthetic process |
| prostaglandin biosynthetic process |
| glycerophospholipid catabolic process |
| lysophospholipase activity |
| phosphatidylserine acyl-chain remodeling |
| arachidonate transport |
| arachidonic acid secretion |
| phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine) |
| phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine) |
| phosphatidylethanolamine acyl-chain remodeling |
| phosphatidylcholine acyl-chain remodeling |
| icosanoid secretion |
| phospholipase A2 activity |
| phosphatidylglycerol metabolic process |
| icosanoid transport |
| phosphatidylserine metabolic process |
| fatty acid derivative transport |
| prostanoid metabolic process |
| prostaglandin metabolic process |
| phospholipid catabolic process |
| unsaturated fatty acid biosynthetic process |
| icosanoid biosynthetic process |
| glycerolipid catabolic process |
| calcium-dependent phospholipid binding |
| long-chain fatty acid transport |
| fatty acid transport |
| phosphatidylcholine metabolic process |
| acid secretion |
| fatty acid derivative biosynthetic process |
| ruffle membrane |
| unsaturated fatty acid metabolic process |
| icosanoid metabolic process |
| cellular response to antibiotic |
| fatty acid biosynthetic process |
| organophosphate catabolic process |
| monocarboxylic acid transport |
| vesicle |
| fatty acid derivative metabolic process |
| phosphatidylinositol metabolic process |
| monocarboxylic acid biosynthetic process |
| ammonium ion metabolic process |
| cellular lipid catabolic process |
| cellular modified amino acid metabolic process |
| carboxylic acid transport |
| organic acid transport |
| lipid transport |
| lipid catabolic process |
| lysosomal membrane |
| carboxylic acid biosynthetic process |
| organic acid biosynthetic process |
| response to antibiotic |
| glycerophospholipid metabolic process |
| lipid localization |
| fatty acid metabolic process |
| phospholipid metabolic process |
| glycerolipid metabolic process |
| organic anion transport |
| monocarboxylic acid metabolic process |
| cellular response to organic cyclic compound |
| lipid biosynthetic process |
| anion transport |
| small molecule biosynthetic process |
| calcium ion binding |
| organophosphate metabolic process |
| carboxylic acid metabolic process |
| response to organic cyclic compound |
| cellular lipid metabolic process |
| oxoacid metabolic process |
| organic acid metabolic process |
| secretion |
| lipid metabolic process |
| ion transport |
| small molecule metabolic process |
| organic substance catabolic process |
| cellular catabolic process |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
No hits were found.
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| HGC6.3 | 0.635 |
| TBC1D3H | 0.487 |
| TBC1D3G | 0.486 |
| ACSF2 | 0.475 |
| RPS12 | 0.475 |
| TCEB3CL | 0.468 |
| MYO1H | 0.465 |
| DTL | 0.465 |
| TBC1D3F | 0.465 |
| TCEB3CL2 | 0.46 |
| C14orf93 | 0.458 |
| AKIRIN2 | 0.458 |
| TCEB3C | 0.455 |
| CDC6 | 0.454 |
| CWC15 | 0.451 |
| MT1E | 0.451 |
| PSMD2 | 0.45 |
| TFIP11 | 0.449 |
| RRN3 | 0.449 |
| DDX56 | 0.447 |
| PSMB2 | 0.447 |
| ORC6 | 0.445 |
| ANKLE1 | 0.44 |
| LRR1 | 0.435 |
| UTP3 | 0.435 |
| S1PR4 | 0.433 |
| SEC13 | 0.433 |
| C1QTNF9B | 0.432 |
| CBWD3 | 0.431 |
| RPS2 | 0.43 |
| GOLGA6B | 0.43 |
| TWISTNB | 0.429 |
| DDTL | 0.429 |
| CTAGE4 | 0.428 |
| RPL6 | 0.424 |
| RANBP2 | 0.423 |
| SNRPA1 | 0.423 |
| CBWD5 | 0.423 |
| RFXANK | 0.422 |
| VASN | 0.422 |
| TBC1D3 | 0.42 |
| RPS3A | 0.42 |
| TSPY1 | 0.419 |
| C2orf27B | 0.419 |
| NARFL | 0.419 |
| TSPY2 | 0.419 |
| CSNK1A1 | 0.418 |
| RPL35 | 0.417 |
| CDC45 | 0.416 |
| RPS5 | 0.414 |
| CCNA2 | 0.414 |
| CBWD6 | 0.413 |
| ZNF219 | 0.413 |
| HIST1H2BE | 0.412 |
| CDC73 | 0.412 |
| TBC1D3K | 0.411 |
| TBC1D3I | 0.411 |
| TBC1D3L | 0.411 |
| NUP54 | 0.411 |
| TBC1D3E | 0.411 |
| RPS14 | 0.41 |
| EIF3G | 0.41 |
| PSMD11 | 0.409 |
| RPS19 | 0.409 |
| PSMC1 | 0.409 |
| TBC1D3C | 0.409 |
| ARHGEF35 | 0.409 |
| PSMD6 | 0.407 |
| HAP1 | 0.405 |
| POLD1 | 0.404 |
| POLR2F | 0.403 |
| ATP6V1C1 | 0.403 |
| TSPY8 | 0.402 |
| CCDC116 | 0.402 |
| WDR87 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 0/739
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 0/28 |
| blood | 0/28 |
| bone | 0/26 |
| breast | 0/33 |
| central nervous system | 0/56 |
| cervix | 0/4 |
| colorectal | 0/17 |
| esophagus | 0/13 |
| fibroblast | 0/1 |
| gastric | 0/16 |
| kidney | 0/21 |
| liver | 0/20 |
| lung | 0/75 |
| lymphocyte | 0/16 |
| ovary | 0/26 |
| pancreas | 0/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 0/15 |
| prostate | 0/1 |
| skin | 0/24 |
| soft tissue | 0/9 |
| thyroid | 0/2 |
| upper aerodigestive | 0/22 |
| urinary tract | 0/29 |
| uterus | 0/5 |
Essentiality in NALM6
- Essentiality Rank: 2091
- Expression level (log2 read counts): -0.03
Expression Distribution
PLA2G4F Expression in NALM6 Cells: -0.03
